Adamis Pharma Drug Patent Portfolio
Adamis Pharma owns 1 orange book drug protected by 1 US patent Given below is the list of Adamis Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141540 | Syringe devices | 20 Oct, 2036 | Active |
Latest Legal Activities on Adamis Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Adamis Pharma.
| Activity | Date | Patent Number |
|---|---|---|
| ||
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Oct, 2021 | US11141540 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Oct, 2021 | US11141540 |
|
Email Notification
Critical
| 23 Sep, 2021 | US11141540 |
|
Issue Notification Mailed
Critical
| 22 Sep, 2021 | US11141540 |
| Dispatch to FDC | 14 Sep, 2021 | US11141540 |
|
Application Is Considered Ready for Issue
Critical
| 14 Sep, 2021 | US11141540 |
|
Issue Fee Payment Received
Critical
| 10 Sep, 2021 | US11141540 |
|
Issue Fee Payment Verified
Critical
| 10 Sep, 2021 | US11141540 |
|
Electronic Review
Critical
| 11 Jun, 2021 | US11141540 |
|
Email Notification
Critical
| 11 Jun, 2021 | US11141540 |
|
Mail Notice of Allowance
Critical
| 11 Jun, 2021 | US11141540 |
|
Notice of Allowance Data Verification Completed
Critical
| 09 Jun, 2021 | US11141540 |
|
Case Docketed to Examiner in GAU
Critical
| 12 May, 2021 | US11141540 |
|
Case Docketed to Examiner in GAU
Critical
| 10 Nov, 2020 | US11141540 |
| Disposal for a RCE / CPA / R129 | 06 Nov, 2020 | US11141540 |
Adamis Pharma's Family Patents
Adamis Pharma Drug List
Given below is the complete list of Adamis Pharma's drugs and the patents protecting them.
1. Symjepi
Symjepi is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141540 | Syringe devices |
20 Oct, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symjepi's drug page